title: The potential inhibitory effect of revaprazan, an acid pump antagonist, on anticoagulation with warfarin.
abstract: Revaprazan is the first acid pump antagonist with a function similar to that of proton pump inhibitors (PPIs). It has a dual action, active suppression of gastric acid secretion and gastric mucosa protection. While PPIs are known to enhance the prolongation of prothrombin time by warfarin, no research has been done on the drug interaction between revaprazan and warfarin. This study was conducted in order to verify the potential drug interaction between revaprazan and warfarin. Omeprazole, a representative PPI, was used as the control for revaprazan. We searched for patients who were given either revaprazan or omeprazole along with warfarin using the medical record database of Seoul National University Hospital between July 2007 and June 2010. Among the 15 patients who took revaprazan and warfarin together, 73.3% (11/15) showed more than 30% reduction of anticoagulation effect by warfarin after revaprazan was added. The revaprazan group showed a significant shortening of prothrombin time during revaprazan administration compared to pre- and post-revaprazan medication (P < 0.05) while the omeprazole group did not show such difference. Revaprazan seems to have cumulative dose-dependent anti-warfarin or anti-coagulation effect, as judged from the fact that the longer medication with revaprazan showed correlation with the shortening of prothrombin time (R = -0.632, P < 0.05). This study shows a possible interaction between revaprazan and warfarin and suggests that revaprazan can cause shortening of prothrombin time. Therefore, when revaprazan is prescribed to patients on warfarin therapy, prothrombin time should be frequently monitored.
authors.affiliation: Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Jae-Woo
authors.initials: JW
authors.lastname: Jung
authors.forename: Hye-Ryun
authors.initials: HR
authors.lastname: Kang
authors.forename: Jae-Woo
authors.initials: JW
authors.lastname: Kwon
authors.forename: Tae-Eun
authors.initials: TE
authors.lastname: Kim
authors.forename: So-Hee
authors.initials: SH
authors.lastname: Lee
authors.forename: Kyoung Sup
authors.initials: KS
authors.lastname: Hong
authors.forename: Kyung-Sang
authors.initials: KS
authors.lastname: Yu
authors.forename: Sang-Heon
authors.initials: SH
authors.lastname: Cho
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000378:metabolism / Q000627:therapeutic use; D000925:Anticoagulants / Q000378:metabolism* / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000378:metabolism / Q000627:therapeutic use; D011517:Prothrombin Time; D054328:Proton Pump Inhibitors / Q000378:metabolism* / Q000627:therapeutic use; D011744:Pyrimidinones / Q000378:metabolism* / Q000627:therapeutic use; D044005:Tetrahydroisoquinolines / Q000378:metabolism* / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy; D014859:Warfarin / Q000378:metabolism* / Q000627:therapeutic use*
chemical_list: D000897:Anti-Ulcer Agents; D000925:Anticoagulants; D054328:Proton Pump Inhibitors; D011744:Pyrimidinones; D044005:Tetrahydroisoquinolines; C108798:YH 1885; D014859:Warfarin; D009853:Omeprazole